Shares of Cocrystal Pharma Inc (OTCMKTS:COCP) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.27 and traded as high as $1.83. Cocrystal Pharma shares last traded at $1.77, with a volume of 729 shares trading hands.
The company has a 50 day moving average of $2.27 and a two-hundred day moving average of $2.46.
Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Cocrystal Pharma by 15.3% in the 2nd quarter. BlackRock Inc. now owns 35,323 shares of the company’s stock valued at $83,000 after purchasing an additional 4,685 shares during the period. Vanguard Group Inc. boosted its position in shares of Cocrystal Pharma by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 360,364 shares of the company’s stock valued at $847,000 after purchasing an additional 15,336 shares during the period. Finally, Wasatch Advisors Inc. boosted its position in shares of Cocrystal Pharma by 5.4% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,152,731 shares of the company’s stock valued at $2,709,000 after purchasing an additional 59,235 shares during the period.
Cocrystal Pharma Company Profile (OTCMKTS:COCP)
Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.
Featured Story: Stock Portfolio Tracker
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.